

# Treatments used among patients with psoriasis: a first look at a new patient-centered psoriasis registry

Alexis Ogdie,<sup>1</sup> Joel M. Gelfand,<sup>1</sup> Laetitia N'Dri,<sup>2</sup> Ying Wu,<sup>2</sup> Thomas Scharnitz,<sup>2</sup> Kaleb Michaud<sup>3,4</sup>

<sup>1</sup>University of Pennsylvania, Philadelphia, PA, USA; <sup>2</sup>Bristol Myers Squibb, Princeton, NJ, USA; <sup>3</sup>University of Nebraska, Lincoln, NE, USA; <sup>4</sup>FORWARD Databank, Wichita, KS, USA

## Synopsis

- With an increase in psoriasis (PsO) treatment options in recent years, PsO management has changed substantially over time<sup>1</sup>
- The FORWARD Psoriasis Registry was created to better understand the needs of patients with PsO and the utilization patterns and impact of available PsO therapies across the US
- This patient-centered PsO registry represents a new approach in dermatology, collecting comprehensive survey data directly from patients across the US instead of routine care visits<sup>2</sup>

## Objective

- To examine the demographics, disease characteristics, and treatments used among patients enrolled in the new patient-centered, FORWARD Psoriasis Registry

## Methods

### Patient population

- FORWARD Psoriasis Registry enrollment began in August 2023
- Physician-diagnosed adult patients with PsO were recruited from:
  - Dermatology offices within a national practice group
  - Patient support program for deucravacitinib
  - The FORWARD registry website

- Patients enrolled on or before December 20, 2023, were included in this analysis

### Statistical analysis

- Demographic, disease, lifestyle, and PsO treatment characteristics were summarized descriptively

## Results

### Enrollee demographics

- A total of 702 patients met inclusion criteria and completed the full enrollment questionnaire
  - Mean age was 52.5 years, 66.3% were female, 87.8% were White
  - Reported comorbidities (Table) were consistent with other population-based studies<sup>3</sup>
- Mean PsO duration was 14.9 years, with severity most often classified as mild or moderate at enrollment
  - Approximately 84.5% of patients had plaque PsO
  - A diagnosis of psoriatic arthritis was reported in 27.8% of patients

Table. Demographics, PsO and lifestyle characteristics

Characteristics	Overall cohort (N = 702)
<b>Demographic characteristics</b>	
Age (years)	
Mean (SD)	52.5 (15.7)
Sex, %	
Female	66.3
Race, %	
White	87.8
Ethnicity, %	
Hispanic	5.8
Health Insurance, %	
Private	75.2
Public	36.3
None	1.7
<b>PsO characteristics</b>	
PsO duration, years	
Mean (SD)	14.9 (15.1)
PsO severity at enrollment, <sup>a</sup> %	
Minimal	21.0
Mild	38.7
Moderate	34.2
Severe	6.2
PsA diagnosis, %	27.8
PsA duration, years	
Mean (SD)	9.4 (9.8)
<b>Lifestyle characteristics</b>	
BMI, kg/m <sup>2</sup>	
Mean (SD)	30.2 (7.3)
Smoking status, %	
Current	7.3
Former	29.0
<b>History of comorbidities,<sup>b</sup> %</b>	
Acne	25.4
ADHD	10.0
Anxiety	40.6
Autoimmune disorders <sup>c</sup>	12.8
Cancer	10.1
Depression	34.6
Diabetes mellitus	13.5
Eczema	13.3
Fatty liver disease	7.4
High cholesterol	33.2
Hypertension	35.3
IBD	12.8
Myocardial infarction	2.0
Obstructive sleep apnea	16.0

<sup>a</sup>Severity is based on percentage of BSA involvement, where "Minimal" = <1%; "Mild" = 1-10%; "Moderate" = 11-30%; "Severe" = >30%. <sup>b</sup>Categories are not mutually exclusive. <sup>c</sup>Autoimmune disorders include axial spondyloarthritis, lupus, multiple sclerosis, rheumatoid arthritis, uveitis. <sup>d</sup>ADHD, attention-deficit/hyperactivity disorder; BMI, body mass index; IBD, inflammatory bowel disease; NSAIDs, nonsteroidal anti-inflammatory drugs; PsA, psoriatic arthritis; PsO, psoriasis; SD, standard deviation.

### PsO therapies at enrollment

- At enrollment, topicals and deucravacitinib were the most commonly used PsO therapies (Figure 1)

### Burden of disease

- Burden of disease was, on average, mild to moderate
  - Mean PsO severity assessment scores are shown in Figure 2
  - More than half of patients (56.6%) reported currently experiencing a PsO flare
  - On scales from 0-10, patients reported mean (standard deviation) scalp itch: 4.5 (3.1), scalp pain: 2.3 (2.8), and scalp flaking: 4.8 (3.3)

Figure 1. Percentage of patients by therapies used at enrollment





Figure 2. PsO severity assessment scales



<sup>a</sup>Scores range from 0 to 100. <sup>b</sup>Scores range from 0 to 10. <sup>c</sup>Median: 4.0. <sup>d</sup>PsO, psoriasis.

### Treatment satisfaction

- Most patients (29.0%) indicated they were neither satisfied nor dissatisfied with treatment (Figure 3)
  - Mean level of treatment satisfaction at enrollment was 1.6 (SD 1.2), with scores ranging from 0-4 and higher scores denoting greater satisfaction

### PsO involvement in special areas

- Most patients (94.0%) reported PsO on the soles of their feet, with very few (12.8%) reporting involvement of the palms (Figure 4)

Figure 3. Treatment satisfaction at enrollment





Figure 4. Special areas of interest<sup>a</sup>



<sup>a</sup>Special areas were not mutually exclusive.

## Conclusions

- The demographics, disease, and lifestyle characteristics of patients within this registry are consistent with the known epidemiology of the broader PsO population
- The FORWARD registry provides proof of concept for studies seeking to understand the natural history of PsO, PsO treatment outcomes, treatment needs of adults with PsO, and long-term outcomes among patients with comorbidities

## References

- Reid C, Griffiths CEM. *Acta Derm Venereol*. 2020;100:adv00032.
- Eissing L, et al. *J Eur Acad Dermatol Venerol*. 2016;30:1100-1106.
- Takeshita J, et al. *J Am Acad Derm*. 2017;76:377-390.

## Acknowledgments

- This study was sponsored by Bristol Myers Squibb
- Writing and editorial assistance was provided by Michon Jackson, PhD, of Peloton Advantage, LLC, an OPEN Health company, funded by Bristol Myers Squibb
- The authors acknowledge Yashwanth Patel for his contributions to registry design, data interpretation, and poster development, along with Tobias Bluhmki and Luis Vaz for their contributions to data analysis

## Disclosures

- AO: Consulting/advisory boards: AbbVie, Amgen, Bristol Myers Squibb, CorEvitas, Gilead, Janssen, Lilly, Novartis, Pfizer, and UCB; Grants: Pfizer to Penn, Novartis to Penn, Amgen to Forward/NDB; Royalties: Novartis to husband
- JMG: Consultant and/or research grant: AbbVie, Amgen, Artax, Boehringer Ingelheim, Bristol Myers Squibb, CellClex Therapeutics, FIDe, GSK, Imbimage, Janssen Biologics, Leo Pharma, Lilly, MoonLake Immunotherapeutics, Neuroderm, Novartis, Pfizer, UCB, and Veolia North America; Copatent holder: Resiquimod; Honoraria: Society for Investigative Dermatology and Healo Dermatology; Board member: International Psoriasis Council and Medical Dermatology Society
- LN'D, YW, and TS: Employees and shareholders: Bristol Myers Squibb
- KM: No conflicts to report

## Scientific Content on Demand

To view a copy of this poster:



Scan the QR code via a barcode reader application

QR codes are valid for 1 year after the congress presentation date.